<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477529</url>
  </required_header>
  <id_info>
    <org_study_id>CA301</org_study_id>
    <nct_id>NCT00477529</nct_id>
  </id_info>
  <brief_title>ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer</brief_title>
  <official_title>A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008&#xD;
      given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the&#xD;
      pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description not necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2007</start_date>
  <completion_date type="Actual">June 2, 2011</completion_date>
  <primary_completion_date type="Actual">June 2, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT's and MTD's</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ABI-008 in this patient population</measure>
    <time_frame>Q12 weeks and End of Study (EOS) and Follow Up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ABI-008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-008</intervention_name>
    <description>nab-docetaxel</description>
    <arm_group_label>ABI-008</arm_group_label>
    <other_name>nab-docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet the following criteria to be enrolled in this study.&#xD;
&#xD;
          1. Patients must have histologically or cytologically confirmed adenocarcinoma of the&#xD;
             prostate that is clinically refractory to hormone therapy.&#xD;
&#xD;
          2. Zubrod Performance Status 0-1.&#xD;
&#xD;
          3. At the time of enrollment, patients must have evidence of progressive metastatic&#xD;
             disease, either:&#xD;
&#xD;
               -  Measurable disease with any level of serum PSA&#xD;
&#xD;
                    -  OR&#xD;
&#xD;
               -  Non-measurable disease with PSA ≥ 5 ng/ml. Patients with PSA ≥ 5 ng/ml only and&#xD;
                  no other radiographic evidence of metastatic prostate cancer are not eligible.&#xD;
&#xD;
          4. Patients must have demonstrated evidence of progressive disease since the most recent&#xD;
             change in therapy. Progressive disease is defined as any one of the following&#xD;
             (measurable disease, bone scan, or PSA progression):&#xD;
&#xD;
               -  Measurable Disease Progression&#xD;
&#xD;
               -  Bone Scan Progression&#xD;
&#xD;
               -  PSA Progression&#xD;
&#xD;
          5. Serum testosterone ≤ 50 ng/ml, determined within two weeks prior to starting&#xD;
             treatment.&#xD;
&#xD;
          6. Maintaining castrate status: Patients who have not undergone surgical orchiectomy&#xD;
             should continue on medical therapies [e.g. gonadotropin releasing hormone analogs&#xD;
             (GnRH analogs)] to maintain castrate levels of serum testosterone.&#xD;
&#xD;
          7. Megestrol acetate (MEGACE®) treatment may continue if patient has been on stable doses&#xD;
             of the drug.&#xD;
&#xD;
          8. Age &gt; 18 years of age.&#xD;
&#xD;
          9. Four weeks since major surgery.&#xD;
&#xD;
         10. The following restrictions on prior therapy for metastatic disease apply:&#xD;
&#xD;
               -  No prior chemotherapy regimen for metastatic disease.&#xD;
&#xD;
               -  No more than one prior course of palliative radiotherapy.&#xD;
&#xD;
               -  Up to one prior treatment with a non-chemotherapeutic agent (e.g., kinase&#xD;
                  inhibitors, immunotherapeutic agents, etc) is permitted as treatment for&#xD;
                  metastatic disease.&#xD;
&#xD;
               -  No prior radioisotope therapy with Strontium-89, Samarium or similar agents.&#xD;
&#xD;
               -  One prior neo-adjuvant or adjuvant chemotherapy regimen is permitted if given&#xD;
                  over 3 years ago.&#xD;
&#xD;
         11. No limitation on prior hormonal therapy.&#xD;
&#xD;
         12. Patients should be off all therapy for at least 4 weeks prior to study drug&#xD;
             administration.&#xD;
&#xD;
         13. Life expectancy should be ≥ 3 months.&#xD;
&#xD;
         14. Patients must have signed an informed consent document stating that they understand&#xD;
             the investigational nature of the proposed treatment.&#xD;
&#xD;
         15. Required Initial Laboratory Data:&#xD;
&#xD;
               -  WBC ≥ 3,000/µl&#xD;
&#xD;
               -  ANC ≥ 1,500/µl&#xD;
&#xD;
               -  Platelet count ≥ 100,000/µl&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x&#xD;
&#xD;
               -  Total Bilirubin ≤ (exceptions will be made for patients with Gilbert's Disease)&#xD;
&#xD;
               -  SGOT (AST) ≤ 1.5 x&#xD;
&#xD;
               -  SGPT (ALT) ≤ 1.5 x&#xD;
&#xD;
         16. Men whose sexual partners are of child-bearing age must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control) for the duration of study&#xD;
             participation.&#xD;
&#xD;
         17. If obese (weight &gt; 20% of ideal body weight) patient must be treated with doses&#xD;
             calculated using adjusted BSA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from the study.&#xD;
&#xD;
          1. Patients may not be receiving any other investigational agents.&#xD;
&#xD;
          2. Patients may continue on a daily Multi-Vitamin, low dose (≤ 400 IU qd) Vitamin D,&#xD;
             Calcitrol (≤ 0.5 mcg qd), and calcium supplements, but all other herbal, alternative&#xD;
             and food supplements (i.e. PC-Spes, Saw Palmetto, St John Wort, etc.) must be&#xD;
             discontinued before registration.&#xD;
&#xD;
          3. Patients on stable doses of bisphosphonates, who develop subsequent tumor progression,&#xD;
             may continue on this medication.However, patients may not initiate bisphosphonate&#xD;
             therapy prior to or during study&#xD;
&#xD;
          4. Patients with known brain metastases.&#xD;
&#xD;
          5. Patients with history of allergic reactions attributed to solvent-based docetaxel&#xD;
             (Taxotere).&#xD;
&#xD;
          6. Patients with significant cardiovascular disease including congestive heart failure,&#xD;
             active angina pectoris or recent myocardial infarction (within the last 6 months).&#xD;
&#xD;
          7. Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers.&#xD;
&#xD;
          8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          9. HIV-positive patients receiving combination anti-retroviral therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Araujo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 21, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2007</study_first_posted>
  <disposition_first_submitted>November 13, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 19, 2019</disposition_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

